A pill a day to prevent HIV? Successes and challenges of pre-exposure prophylaxis in the real world

Pre-exposure prophylaxis (PrEP) is a pill composed of two antiretroviral drugs (tenofovir disoproxil fumarate and emtricitabine, or TDF/FTC) that prevents HIV infection. Numerous studies have now shown that when taken daily, this medication has the potential to dramatically reduce the risk of HIV transmission among populations at highest risk. TDF/FTC as PrEP was approved by the United States Food and Drug Administration (FDA) in 2012. Despite its success in clinical trials and endorsement by the FDA, use of PrEP has been low. A primary concern of PrEP research now is identifying and addressing barriers to successful PrEP implementation. Only a small fraction of people who could benefit from PrEP know about it; even fewer know how or are able to access PrEP, and fewer still actually obtain a prescription for PrEP. When people are prescribed the medication, there are also potential barriers to being retained in care and taking it every day as prescribed.

Fig. 1. Retention in HIV pre-exposure prophylaxis (PrEP) care cascade overall and for Rhode Island, Mississippi, and Missouri. Blue bars indicate the number of patients who received a prescription for PrEP (and had been in the program for six or more months), red bars indicate the number who initiated PrEP (confirmed to have started the medication), green bars indicate the number who were retained in PrEP care at three months, and purple bars indicate the number who were retained in PrEP care at six months.

In 2013, our team implemented clinical PrEP programs in three cities: Providence, Rhode Island; Jackson, Mississippi; and St. Louis, Missouri. These were among the first non-research trial PrEP programs in the country. In an effort to evaluate what happens in a “real-world” setting when people are prescribed PrEP, we analyzed data on patient outcomes, including adherence to daily dosing and retention in care.

People who are prescribed PrEP should see their medical provider every three months to test for HIV and monitor possible side effects, and to receive a prescription for the following three months. Of all the people prescribed PrEP across the three sites, only 73% followed up with a medical provider three months later, and only 60% followed up six months later. These numbers were markedly low and were similar across all three sites.  Over the observation period, three patients who were prescribed PrEP acquired HIV. One likely already had HIV when first prescribed PrEP, one had low adherence to the medication, and one acquired HIV just before actually starting the medication.

Overall, this implementation experience has shown that there was interest in PrEP, and people were able to access PrEP care. However, a high proportion of people did not follow up for reasons that are still unknown. This loss to follow-up is an important area for future study: once we understand these reasons, we can design programs and interventions to keep patients retained in PrEP care and adherent to the medication.

Madeline C. Montgomery, Philip A. Chan
Division of Infectious Diseases, Warren Alpert Medical School of Brown University,
The Miriam Hospital, Providence, RI, USA

 

Publication

Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities.
Chan PA, Mena L, Patel R, Oldenburg CE, Beauchamps L, Perez-Brumer AG, Parker S, Mayer KH, Mimiaga MJ, Nunn A
J Int AIDS Soc. 2016 Jun 13

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

Leave a Reply